122 related articles for article (PubMed ID: 38812074)
1. Population pharmacokinetic modeling of sotatercept in healthy participants and patients with pulmonary arterial hypertension.
Ait-Oudhia S; Jaworowicz D; Hu Z; Bihorel S; Hu S; Balasubrahmanyam B; Mistry B; de Oliveira Pena J; Wenning L; Gheyas F
CPT Pharmacometrics Syst Pharmacol; 2024 May; ():. PubMed ID: 38812074
[TBL] [Abstract][Full Text] [Related]
2. Population Pharmacokinetics of Tadalafil in Pediatric Patients with Pulmonary Arterial Hypertension: A Combined Adult/Pediatric Model.
Ferguson-Sells L; Velez de Mendizabal N; Li B; Small D
Clin Pharmacokinet; 2022 Feb; 61(2):249-262. PubMed ID: 34379314
[TBL] [Abstract][Full Text] [Related]
3. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension.
Hoeper MM; Badesch DB; Ghofrani HA; Gibbs JSR; Gomberg-Maitland M; McLaughlin VV; Preston IR; Souza R; Waxman AB; Grünig E; Kopeć G; Meyer G; Olsson KM; Rosenkranz S; Xu Y; Miller B; Fowler M; Butler J; Koglin J; de Oliveira Pena J; Humbert M;
N Engl J Med; 2023 Apr; 388(16):1478-1490. PubMed ID: 36877098
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies.
Yang F; Paccaly AJ; Rippley RK; Davis JD; DiCioccio AT
J Pharmacokinet Pharmacodyn; 2021 Aug; 48(4):479-494. PubMed ID: 33728546
[TBL] [Abstract][Full Text] [Related]
5. Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program.
Yapa SW; Roth D; Gordon D; Struemper H
Lupus; 2016 Nov; 25(13):1448-1455. PubMed ID: 27072354
[TBL] [Abstract][Full Text] [Related]
6. Population Pharmacokinetic Modeling of Benralizumab in Adult and Adolescent Patients with Asthma.
Yan L; Wang B; Chia YL; Roskos LK
Clin Pharmacokinet; 2019 Jul; 58(7):943-958. PubMed ID: 30854591
[TBL] [Abstract][Full Text] [Related]
7. The Impact of Immunogenicity on the Pharmacokinetics, Efficacy, and Safety of Sotatercept in a Phase III Study of Pulmonary Arterial Hypertension.
Liao K; Mackenzie H; Ait-Oudhia S; Manimaran S; Zeng Y; Akers T; Yun T; de Oliveira Pena J
Clin Pharmacol Ther; 2024 Mar; 115(3):478-487. PubMed ID: 38012534
[TBL] [Abstract][Full Text] [Related]
8. Treating Pulmonary Arterial Hypertension With Sotatercept: A Meta-Analysis.
Uddin N; Ashraf MT; Sam SJ; Sohail A; Ismail SM; Paladini A; Syed AA; Mohamad T; Varrassi G; Kumar S; Khatri M
Cureus; 2024 Jan; 16(1):e51867. PubMed ID: 38327917
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of tanezumab following intravenous or subcutaneous administration to patients with osteoarthritis or chronic low back pain.
Shoji S; Suzuki A; Gaitonde P; Cai CH; Marshall S
Br J Clin Pharmacol; 2022 Jul; 88(7):3321-3334. PubMed ID: 35112378
[TBL] [Abstract][Full Text] [Related]
10. Population Health Model Predicting the Long-Term Impact of Sotatercept on Morbidity and Mortality in Patients with Pulmonary Arterial Hypertension (PAH).
McLaughlin V; Alsumali A; Liu R; Klok R; Martinez EC; Nourhussein I; Bernotas D; Chevure J; Pausch C; De Oliveira Pena J; Lautsch D; Hoeper MM
Adv Ther; 2024 Jan; 41(1):130-151. PubMed ID: 37851297
[TBL] [Abstract][Full Text] [Related]
11. Population PK and IgE pharmacodynamic analysis of a fully human monoclonal antibody against IL4 receptor.
Kakkar T; Sung C; Gibiansky L; Vu T; Narayanan A; Lin SL; Vincent M; Banfield C; Colbert A; Hoofring S; Starcevic M; Ma P
Pharm Res; 2011 Oct; 28(10):2530-42. PubMed ID: 21604075
[TBL] [Abstract][Full Text] [Related]
12. SPECTRA Phase 2b Study: Impact of Sotatercept on Exercise Tolerance and Right Ventricular Function in Pulmonary Arterial Hypertension.
Waxman AB; Systrom DM; Manimaran S; de Oliveira Pena J; Lu J; Rischard FP
Circ Heart Fail; 2024 May; 17(5):e011227. PubMed ID: 38572639
[TBL] [Abstract][Full Text] [Related]
13. Is sotatercept, which traps activins and growth differentiation factors, a new dawn in treating pulmonary arterial hypertension (PAH)?
Doggrell SA
Expert Opin Biol Ther; 2023; 23(7):589-593. PubMed ID: 37269300
[TBL] [Abstract][Full Text] [Related]
14. Model-based clinical pharmacology profiling and exposure-response relationships of the efficacy and biomarker of lebrikizumab in patients with moderate-to-severe asthma.
Zhu R; Zheng Y; Dirks NL; Vadhavkar S; Jin JY; Peng K; Holweg CTJ; Olsson J; Matthews JG; Putnam WS
Pulm Pharmacol Ther; 2017 Oct; 46():88-98. PubMed ID: 28843617
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics and the pharmacokinetic/pharmacodynamic relationship of riociguat in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.
Saleh S; Becker C; Frey R; Mück W
Pulm Circ; 2016 Mar; 6(Suppl 1):S86-96. PubMed ID: 27162632
[TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials.
Diao L; Hang Y; Othman AA; Nestorov I; Tran JQ
Clin Pharmacokinet; 2016 Aug; 55(8):943-55. PubMed ID: 26873229
[TBL] [Abstract][Full Text] [Related]
17. Population Pharmacokinetics (PK) and Pharmacodynamics (PD) Analysis of LY3015014, a Monoclonal Antibody to Protein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Healthy Subjects and Hypercholesterolemia Patients.
Shen T; James DE; Krueger KA
Pharm Res; 2017 Jan; 34(1):185-192. PubMed ID: 27822850
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetic modeling of ilaprazole in healthy subjects and patients with duodenal ulcer in China.
Yu M; Liu S; Wu X; Wang H
Front Pharmacol; 2023; 14():1306222. PubMed ID: 38269273
[No Abstract] [Full Text] [Related]
19. Population pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus.
Narwal R; Roskos LK; Robbie GJ
Clin Pharmacokinet; 2013 Nov; 52(11):1017-27. PubMed ID: 23754736
[TBL] [Abstract][Full Text] [Related]
20. Population Pharmacokinetic Analysis of Dorzagliatin in Healthy Subjects and Patients with Type 2 Diabetes Mellitus.
Wang K; Feng L; Zhang J; Zou Q; Xu F; Sun Z; Tang F; Chen L
Clin Pharmacokinet; 2023 Oct; 62(10):1413-1425. PubMed ID: 37537410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
